An in vivo study revealed significant improvements in haematuria and proteinuria, as well as preservation of kidney function in a murine model of ANCA-associated vasculitis treated with 14 days of fostamatinib, the most notable SYK-inhibitor [59]. The gene discussed is SYK; the disease is anti-neutrophil cytoplasmic antibody-associated vasculitis.